Lexeo Therapeutics provides updates on their gene therapy programme for Friedreich’s ataxia cardiomyopathy
On March 24th 2025, the pharmaceutical company Lexeo Therapeutics provided a number of updates on their phase 1/2 trial of the gene therapy drug LX2006 for Friedreich’s ataxia (FA) cardiomyopathy. […]